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Summary
In adult brains, ionotropic or metabotropic purinergic receptors are widely expressed in neurons and glial cells. They play an essential
role in inflammation and neurotransmission in response to purines secreted to the extracellular medium. Recent studies have
demonstrated a role for purinergic receptors in proliferation and differentiation of neural stem cells although little is known about their
role in regulating the initial neuronal development and axon elongation. The objective of our study was to investigate the role of some
different types of purinergic receptors, P2Y1, P2Y13 and P2X7, which are activated by ADP or ATP. To study the role and crosstalk of
P2Y1, P2Y13 and P2X7 purinergic receptors in axonal elongation, we treated neurons with specific agonists and antagonists, and we
nucleofected neurons with expression or shRNA plasmids. ADP and P2Y1–GFP expression improved axonal elongation; conversely,
P2Y13 and ATP-gated P2X7 receptors halted axonal elongation. Signaling through each of these receptor types was coordinated by
adenylate cyclase 5. In neurons nucleofected with a cAMP FRET biosensor (ICUE3), addition of ADP or Blue Brilliant G, a P2X7
antagonist, increased cAMP levels in the distal region of the axon. Adenylate cyclase 5 inhibition or suppression impaired these cAMP
increments. In conclusion, our results demonstrate a crosstalk between two metabotropic and one ionotropic purinergic receptor that
regulates cAMP levels through adenylate cyclase 5 and modulates axonal elongation triggered by neurotropic factors and the PI3K–Akt–
GSK3 pathway.
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Introduction
Most early studies of the roles of nucleotides in development have
examined their intracellular roles. However, it is now generally
accepted that purines and pyrimidines have potent extracellular
actions mediated by the activation of specific membrane receptors.
The role of purinergic signaling during developmental and
pathological states is only now beginning to be explored because
of the large number of purinergic receptor subtypes involved and
because purines have effects on every major cell type present in the
CNS. ATP is released by different cell types in response to
multiple physiological stimuli, as well as after programmed or
injury-induced cell death, and can be converted into other purines,
such as ADP, AMP or adenosine by the action of extracellular
ectonucleotidases (Burnstock, 2007). ATP, ADP or adenosine can
activate purinergic receptors, which are subdivided in P1 and P2
receptors. The P2 receptor family consists of cationic ATP-
operated P2X receptors, and the metabotropic G-protein-coupled
P2Y receptors, which are activated by different purines and
pyrimidines, among them ADP (Abbracchio et al., 2009).
Although our understanding of the pathways of intercellular
purinergic signaling is still limited, it is clear that purinergic
signaling represents a main non-synaptic signaling mechanism in
the normal and diseased CNS. Acting at purinergic receptors,
extracellular purines can regulate neurotransmission and
developmental events, such as cell migration or apoptosis, and
they have been implicated in several central nervous system
disorders (Burnstock, 2007; Burnstock, 2008). Recent studies have
shown that inhibition of the ATP-gated P2X7 receptor improves
recovery after spinal cord injury (Peng et al., 2009; Wang et al.,
2004), promotes axonal growth in hippocampal neurons (Diaz-
Hernandez et al., 2008) and induces N2a cell differentiation
(Gomez-Villafuertes et al., 2009).
The regulation of axonal elongation is an important feature
during neuronal development and axonal recovery after axonal
injury, in order to achieve functional neuronal connectivity.
Neurotrophic factors, axon guidance molecules and
neurotransmitter receptors play an essential role in this process
(Huang and Reichardt, 2001; Mueller, 1999; Ruediger and Bolz,
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2007). However, the potential role in nervous system development
of purinergic receptors and more precisely that of dinucleoside
polyphosphates, such as ADP, which can activate various P2Y
receptors, has not yet been investigated. The coordination of
purinergic receptors specific for different purines also requires
further investigation.
The P2Y receptor family can be subdivided into two
subgroups: Gq- or G11-coupled P2Y1, 2, 4, 6 and 11 receptors;
and Gi- or Go-coupled P2Y12, 13 and 14 receptors (Abbracchio
et al., 2006; Burnstock, 2007). P2Y receptors are expressed in the
CNS, in both glia and neurons and they are known to couple to
neuronal ion channels (Boehm, 2003) and to modulate pain
responses (Malin and Molliver, 2010). P2Y1, P2Y12 and P2Y13
are preferentially activated by ADP (Burnstock, 2007). The P2Y1
receptor plays an important role in neurosphere proliferation
(Mishra et al., 2006) and the radial migration of cortical neurons
(Liu et al., 2008). P2Y13 is also implicated in regulating CNS
neurons (Ortega et al., 2008). Both P2Y1 and P2Y13 are
expressed in hippocampal neurons (Csolle et al., 2008) and the
Allen Brain Atlas; http://www.brain-map.org/), whereas P2Y12
has been described in rat brainstem, dorsal root ganglion neurons
(Heinrich et al., 2008) and oligodendrocytes, but it is absent from
hippocampal and neocortical neurons (Amadio et al., 2006;
Hollopeter et al., 2001).
In the context of axonal growth improvement after axonal
injury, we have employed a widely used model of embryonic
cultured hippocampal neurons with the objective of
understanding how different purines and purinergic receptors,
such as P2X7, P2Y1 or P2Y13, can regulate axonal elongation
and how they are coordinated. Because these receptors are widely
expressed in neurons and glial cells, the study was performed in a
widely used model of pure cultured hippocampal neurons in the
absence of glial cells. We show that ADP promotes axonal
elongation through the P2Y1 receptor, whereas the P2Y13
receptor exerts a negative effect on axonal elongation, as
described previously for the ATP-gated P2X7 receptor (Diaz-
Hernandez et al., 2008). All three receptors are expressed in the
distal region of the axon and modulate signaling pathways that
involve extracellular calcium influx (assisted by P2X7) and the
Gq (P2Y1) and Gi (P2Y13) proteins. The coordinated action of
these three signaling pathways contributes to the fine regulation
of adenylate cyclase 5 (AC5, also known as ADCY5), which
modulates cAMP levels and axon elongation by modulating, the
PI3K–Akt–GSK3 pathway.
Results
ADP regulates axonal elongation in cultured hippocampal
neurons through the P2Y1 and P2Y13 receptors
In the light of previous results demonstrating how ATP
modulates axon elongation through the ionotropic P2X7
receptor (Diaz-Hernandez et al., 2008), we analyzed whether
ADP, acting through the metabotropic P2Y1 and P2Y13
receptors, can regulate axonal elongation. Both these receptors
are expressed in the hippocampus and hippocampal neurons
(supplementary material Fig. S1) and are specific for ADP
(Burnstock, 2007). In our model of cultured hippocampal
neurons, both receptors were found in the axon, with a more
intense signal in the distal region of the axon (Fig. 1). The
fluorescence of both P2Y1 and P2Y13 colocalized with
microtubules in the distal region of the axon and with the actin
region of growth cones. Both receptors were also detected in the
neuronal soma and to a lesser extent in the future dendrites.
Fig. 1. P2Y1 and P2Y13 receptors are localized in the distal axon of cultured hippocampal neurons. (A,B) Hippocampal neurons after 3 DIV, stained with
antibodies against a-tubulin (blue) and Alexa-Fluor-594–phalloidin (red) to visualize neuronal morphology, and P2Y1 (A) or P2Y13 (B, green). Scale bar:
100 mm. Boxes indicate the area of the distal region of the axon magnified in the panels on the right. (C,D) Graphs of P2Y1 and P2Y13 fluorescence (means ±
s.e.m.) in 10 mm sections along the length of the axon. Axons approximately 250 mm long were analyzed in five neurons in two separate experiments. (E) Box-
plot showing the distribution of fluorescence intensities of P2Y1 and P2Y13 receptors in the proximal (0–120 mm) and distal (120–250 mm) regions of the axon.
There was a significant increased in the fluorescence signal for both receptors in the distal region of the axon compared with the proximal region; ***P,0.001.
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The influence of ADP on axon elongation was examined in
hippocampal neurons treated with increasing concentrations of
ADP (1 nM, 100 nM, 500 nM, 1 mM, 5 mM or 10 mM) on the
first day in vitro (1 DIV) until 3 DIV (Fig. 2B). ADP
significantly increased axon length when compared with
control untreated neurons (177.88±5.6 mm), with a maximum
effect at 5 mM (433.55±18.69 mm) and an ED50 of ,1 mM
(Fig. 2A,B). We then assessed the effect of ADP (5 mM) or 2-
MeSADP (5 mM) on axon length, the latter is an ADP analogue
with equal or greater specificity for P2Y1 and P2Y13 purinergic
receptors (Fig. 2A,C). Both 2-MeSADP and ADP enhanced
axon growth to a similar extent (342.76±9.99 mm and
347.70±11.12 mm, respectively) compared with control neurons
(150.47±3.42 mm). By contrast, the addition of 1 mM ATP to
cultured hippocampal neurons in the same conditions retarded
axonal growth (114.12±4.97 mm vs 174.25±6.98 mm in control
neurons; Fig. 2A,C).
Activation of P2Y1 and P2Y13 receptors by ADP exerts
opposing effects on axon elongation
To identify the role of each receptor in axon elongation neurons
were cultured for 3 DIV and treated for the last 48 hours with the
P2Y1 antagonist, MRS-2179 or the P2Y13 antagonist, MRS-
2211 at different concentrations (supplementary material Fig.
S2). Treatment with the P2Y1 antagonist MRS-2179 significantly
retarded axonal growth (86.62±2.30 mm at 0.5 mM and
70.54±1.94 mm at 1 mM, respectively), and treatment with the
P2Y13 antagonist MRS-2211 (1, 5 or 10 mM) significantly
increased axonal growth (379.48±12.99 mm, 405.39±13.14 mm
and 428.39±13.68 mm, respectively) compared with that of
control neurons (150.47±3.42 mm), suggesting that the P2Y13
receptor negatively regulates axon elongation. Moreover, neurons
cultured in the presence of MRS-2179 (1 mM) and ADP (5 mM)
did not generate significantly longer axons (173.14±8.47 mm)
than control neurons (156.92±5.69 mm), indicating that the
influence of ADP on axon elongation is mediated by the P2Y1
receptor (Fig. 2D,E). Furthermore, the increase in axon length in
the presence of both ADP and MRS-2211 was similar to that
when either compound was used alone (Fig. 2D,E).
The effects of the specific antagonists of P2Y1 and P2Y13 were
confirmed by interference short hairpin RNAs (shRNAs) for P2Y1
or P2Y13 receptors (Fig. 3). The axons produced by neurons
nucleofected with the scrambled (control) shRNA plasmid reached
a length of 164.53±3.73 mm, whereas nucleofection with P2Y1
shRNA 1 or P2Y1 shRNA 2 resulted in lengths of 97.60±3.25 mm
and 134.66±3.78 mm, respectively (Fig. 3A,C). This reduction in
axonal growth was correlated with a decrease in P2Y1 protein
expression produced by each shRNA (Fig. 3B,J). Moreover,
treatment with ADP (5 mM) promoted axonal growth in neurons
nucleofected with the scrambled shRNA (395.67±10.57 mm) but
not in those nucleofected with P2Y1 shRNA 1 (163.29±5.22 mm
vs 223.53±5.37 mm in scrambled-shRNA-nucleofected neurons:
Fig. 2. ADP modulates axon elongation through the P2Y1 and P2Y13 purinergic receptors. (A) Hippocampal neurons cultured in the presence or absence of
ADP (5 mM), ATP (1 mM) or the ADP analogue 2MeSADP (5 mM), from day 1 to day 3 in vitro. Neurons were fixed at 3 DIV and stained with antibodies against
MAP2 (red, somatodendritic) and Tau-1 (green, axon) to define the neuronal morphology and quantify axon length. (B) Axon length of hippocampal neurons at 3
DIV following treatment with increasing concentrations of ADP (0.1, 0.5, 1, 5 and 10 mM). The resulting curve revealed an ED50 of 0.879 mM, with a maximum
effect at 5 mM ADP. (C) Axon length at 3 DIV following treatment with ADP (5 mM), 2MeSADP (5 mM) and ATP (1 mM). Data are means ± s.e.m. from three
independent experiments from 100 neurons analyzed in each experiment and condition. (D) Hippocampal neurons incubated with the P2Y1 antagonist (MRS-
2179) or the P2Y13 antagonist (MRS-2211) from day 1 to day 3 in vitro, in the presence or absence of ADP (5 mM). Neurons were stained with MAP2 and Tau-1
antibodies, and the length of their axon was quantified. (E) Graphs of the mean axon lengths ± s.e.m. of the control and treated neurons shown in D. All data are
the means ± s.e.m. from three independent experiments with 100 neurons analyzed in each experiment and condition; ***P,0.001. n.s., non-significant
differences. Scale bars: 50 mm.
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Fig. 3D,E). In contrast to the P2Y1 shRNAs, nucleofection
with plasmids expressing P2Y13 shRNA 1 or P2Y13 shRNA
2 (Fig. 3A,C) approximately doubled the length of axons
(255.79±7.17 mm or 325.05±9.23 mm, respectively) when
compared with neurons nucleofected with scrambled shRNA
(164.53±3.73 mm).
In accordance with these results, the expression of P2Y1–GFP
increased mean axon length to 324.24±9.24 mm (Fig. 3I,K),
Fig. 3. P2Y1 silencing impairs ADP-dependent axon elongation. (A) Hippocampal neurons were nucleofected with scrambled shRNA, P2Y1 shRNA or P2Y13
shRNA. Neurons were fixed at 3 DIV and stained with an anti-a-tubulin antibody. Nucleofected neurons were identified by their GFP fluorescence. (B) HEK-
293T cells were co-transfected with GFP, P2Y1–GFP or P2Y13 plasmids, in combination with different P2Y1 or P2Y13 shRNAs. Data are means ± s.e.m. of three
independent experiments. P2Y1–GFP and P2Y13 protein expression was normalized to a-tubulin expression levels; ***P,0.001. (C) Axon length of
hippocampal neurons expressing scrambled shRNA, two different P2Y1 shRNAs or two different P2Y13 shRNAs was quantified after staining with antibodies
against MAP2 and Tau-1. Data are mean axon lengths ± s.e.m. from three independent experiments, analyzing 100 neurons for each condition in each experiment;
***P,0.001. The dotted grey line indicates the mean axon length of scrambled-shRNA-nucleofected neurons. (D,E) Hippocampal neurons nucleofected with
scrambled shRNA or P2Y1 shRNA and treated with ADP (5 mM) from day 1 to day 3 in vitro. The graph in D shows the axon length in nucleofected neurons
(GFP-positive) incubated in the presence or absence of ADP. (F–H) Hippocampal neurons nucleofected with scrambled shRNA, P2Y1 shRNA or P2Y13 shRNA
and treated with the P2Y1 antagonist (MRS-2179) or the P2Y13 antagonist (MRS-2211) from day 1 to day 3 in vitro. Scale bars: 50 mm. Note that in all cases
P2Y1 expression and function is necessary for axon elongation. Data in G are the mean axon lengths ± s.e.m. from three independent experiments, analyzing 100
neurons for each condition in each experiment; ***P,0.001. H shows the distribution of the axon length for all neurons from three independent experiments for
each condition (n5300). (I) Hippocampal neurons that had been nucleofected with plasmids expressing GFP, P2Y1–GFP and P2Y13. After 3 DIV neurons were
stained for MAP2 and Tau-1 to identify the axon. (J) P2Y1 or P2Y13 mean fluorescence intensity along the axon in control, scrambled shRNA, P2Y1 shRNA or
P2Y13 shRNA nucleofected neurons. (K) Graph of the mean axon lengths ± s.e.m. of neurons nucleofected with GFP, P2Y1–GFP or P2Y13 and GFP. Neurons
were quantified in three independent experiments, analyzing 100 neurons for each condition in each experiment; ***P,0.001. Scale bars: 100 mm. Box-plot
shows the distribution of axon lengths for all the neurons quantified in K.
AC5 coordinates purine receptors in axon growth 179
J
o
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
whereas co-nucleofection with plasmids expressing P2Y13 and
GFP resulted in a mean axon length of 91.36±4.76 mm; the axon
length of the control neurons was 164.53±3.73 mm.
We analyzed the relative contributions of P2Y1 activation and
P2Y13 inhibition to axon growth (Fig. 3F–H) by nucleofecting
neurons with the scrambled shRNA or P2Y13 shRNA 2 and
treating them with the P2Y1 antagonist, MRS-2179. The increase
in axon length following P2Y13 suppression (290.43±9.86 mm vs
181.70±6.96 mm in non-treated scrambled shRNA nucleofected
neurons) was blocked by P2Y1 antagonism (137.08±4.67 mm).
Similarly, the increase in axonal length seen in neurons treated
with the P2Y13 antagonist, MRS-2211, was impaired in neurons
expressing P2Y1 interference RNA 1 (127.27±4.14 mm). Taken
together, these findings indicate that P2Y1 activation is necessary
and sufficient to promote axon elongation, whereas P2Y13
activation might inhibit this effect.
ADP-mediated axon elongation is dependent upon the
status of P2X7
ATP negatively regulates axon growth through the activation of
the P2X7 receptor, whereby the inhibition or suppression P2X7
enhances axon growth. The immunofluorescence pattern of P2X7
revealed the same localization that P2Y1 and P2Y13 receptors
in the hippocampus as previously described (Fig. 4E) (Diaz-
Hernandez et al., 2008). To understand the relationship between
P2X and P2Y purinergic receptors, hippocampal neurons were
nucleofected with a construct expressing the P2X7 receptor
coupled to GFP, or with GFP alone, and treated with ADP
(5 mM) from day 1 to day 3 in vitro, as described above.
Interestingly, ADP treatment increased axon length in GFP-
nucleofected neurons, but failed to do so in those expressing
P2X7–GFP (Fig. 4A,B). In the same sense, axons of P2Y1–GFP-
expressing neurons treated with ATP (1 mM) were shorter than
those of untreated GFP-nucleofected neurons (Fig. 4A,B). P2X7
inhibition with Blue Brilliant G (BBG; 100 nM) reversed the
slow axon growth seen in neurons expressing either P2Y1
shRNAs or the P2Y13 receptor, resulting in an increase in axon
length (Fig. 4C), which was significantly lower than in scrambled
shRNA- or GFP-nucleofected neurons treated with BBG.
Furthermore, P2X7 shRNAs abolished the effects of inhibiting
the P2Y1 receptor with MRS-2179, whereas P2X7–GFP
expression impaired the axon growth-promoting effect of the
P2Y13 antagonist, MRS-2211 (Fig. 4D). These results suggest
that P2X7 activation by ATP blocks an ADP-mediated signaling
mechanism that is regulated by P2Y1 and by P2Y13.
Adenylate cyclase activity is necessary for the regulation
of axonal elongation by P2Y1, P2Y13 and P2X7
To test the hypothesis that a common signaling pathway
integrates P2Y1-, P2Y13- and P2X7-mediated signaling, we
Fig. 4. P2X7 impairs ADP-P2Y1-dependent axon elongation. (A) Hippocampal neurons nucleofected with GFP, P2Y1–GFP and P2X7–GFP and cultured in
the presence or absence of ADP (5 mM) from day 1 to day 3 in vitro. Neurons were stained with an anti-Tau-1 antibody (red) to visualize the axon, and
nucleofected neurons were identified by GFP fluorescence. Scale bar: 100 mm. (B–D) Axon length was quantified in neurons nucleofected with the plasmids
indicated in each graph. Bars show the mean axon length in neurons treated with (white) or without (black) the indicated P2 agonist or antagonist. Data are the
mean axon lengths ± s.e.m. from three independent experiments, analyzing 100 neurons for each condition in each experiment; ***P,0.001, n.s., not significant.
(E) P2X7 expression in a 3 DIV hippocampal neuron stained with anti-a-tubulin (blue), P2X7 (green) and Alexa-Fluor-594–phalloidin (red).
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first investigated whether the effects of P2Y1 inhibition or
exogenous P2Y13 expression could be reversed by activating or
inhibiting their associated G proteins (supplementary material
Fig. S3A–D). Treating neurons from day 1 to day 3 in vitro with
rPMT (20 ng/ml), a recombinant peptide that activates Gq,
reversed the inhibitory effect of MRS-2179 on P2Y1 and
promoted axon growth (230.46±8.54 mm vs 128.69±4.67 mm in
MRS-2179-treated neurons or vs 156.55±5.25 mm in control
neurons). Moreover, inhibition of phospholipase C activity,
which is activated by Gq, attenuated axon elongation in the
presence of ADP (supplementary material Fig. S3E,F). Inhibition
of Gi with pertussis toxin (PTX) reversed the reduced growth
provoked by exogenous P2Y13 expression (323.76±12.22 mm vs
133.67±6.08 mm in exogenous P2Y13-expressing neurons vs
197.19±9.24 mm in GFP-expressing neurons; supplementary
material Fig. S3B,D). On the basis of these findings, we next
sought to identify common signaling components that can be
regulated in opposite directions by Gi and Gq proteins, such as
adenylate cyclases 1, 3, 5, 6, 8 and 9 (Willoughby and Cooper,
2007).
We investigated the common signaling hypothesis in
hippocampal primary cultures using four different experimental
approaches (Fig. 5): (1) administration of an adenylate cyclase
inhibitor (SQ-22536; 20 mM); (2) activation of adenylate cyclase
with forskolin (5 mM); (3) administration of a competitive
antagonist of cAMP-induced activation of PKA (cAMPS-Rp;
Fig. 5. Adenylate cyclase activity is necessary for ADP–P2Y1-dependent axon elongation. (A) Hippocampal neurons treated with the indicated compounds
from day 1 to day 3 in vitro and stained for MAP2 and Tau-1. Scale bar: 100 mm. (B) Axon length in neurons treated with vehicle (black bars) or the indicated
adenylate cyclase or cAMP regulators (white bars), in combination with agonists or antagonists of P2Y1 or P2Y13. Graphs represent the mean axon length ±
s.e.m. from three independent experiments, analyzing 100 neurons for each condition in each experiment; ***P,0.001, **P,0.01; n.s., not significant.
(C,E) Hippocampal neurons nucleofected with P2Y1 shRNA and stained at 3 DIV for Tau-1 or a-tubulin (red). Nucleofected neurons were identified by GFP
fluorescence. Neurons were treated with the adenylate cyclase activator forskolin (5 mM) or a PDE4 inhibitor (20 nM). Note that both treatments reversed the
negative effects of P2Y1 silencing or P2Y13 expression on axon elongation. The graphs in E show the axonal lengths ± s.e.m. from three independent
experiments, analyzing 100 GFP positive neurons for each condition in each experiment; ***P,0.001. (D,F) Neurons nucleofected with P2X7 shRNA or P2X7–
GFP expression plasmids and treated from day 1 to day 3 in vitro with the adenylate cyclase inhibitor (SQ-22536) or the adenylate cyclase activator forskolin,
respectively. Note that adenylate cyclase activation or increased cAMP levels reversed the negative effect of P2X7–GFP expression on axon elongation. The
graphs in F show the axon length ± s.e.m. from three independent experiments analyzing 100 neurons for each condition in each experiment; ***P,0.001. Scale
bars: 100 mm.
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20 mM) or a PKA inhibitor (H-89; 5 mM); and (4) selective
inhibition of the predominant phosphodiesterases in brain,
PDE4B and PDE4D (Iona et al., 1998) with 3,5-dimethyl-1-(3-
nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester (20 nM).
These treatments were administered in combination with
different agonists or antagonists of P2Y1 and P2Y13 receptors
(Fig. 5A,B), as well as in cells in which P2Y1 or P2X7
expression was suppressed with shRNAs, or enhanced with
expression of P2Y13 or P2X7–GFP (Fig. 5C–F).
Neurons were first treated with ADP and the adenylate cyclase
inhibitor (SQ-22536), which attenuated ADP-mediated axon
elongation (152.54±4.43 mm vs 367.85±10.69 mm in neurons
treated with ADP alone) and reduced axon growth to below
control values (189.19±5.57 mm in non-treated neurons;
Fig. 5A,B). The reduction of axon growth in response to
adenylate cyclase inhibition (134.25±3.49 mm) was similar to
that observed following P2Y1 inhibition with MRS-2179
(146.64±6.63 mm), although no further decrease in axon growth
was observed following co-administration of SQ-22536 and
MRS-2179 (137.50±6.66 mm). SQ-22536 administration failed
to reduce axon growth in the presence of dbcAMP
(298.30±12.39 mm vs 322.72±15.42 mm in neurons treated with
dbcAMP alone) and furthermore, inhibition of adenylate cyclase
blocked axon elongation when P2Y13 was inhibited with MRS-
2211 (150.88±5.07 mm vs 362.01±10.75 mm). The inhibitory
effect of MRS-2179 (128.69±4.67 mm vs 156.55±5.25 mm in
control neurons) was reversed by co-administration of 5 mM
forskolin (199.06±6.80 mm). Similarly, forskolin reversed the
inhibition of axon elongation provoked by P2Y1 shRNA or
exogenous P2Y13 expression (Fig. 5C,E). Inhibition of
phosphodiesterase 4 induced axon elongation in the presence
of the P2Y1 antagonist MRS-2179 (337.90±10.84 mm vs
138.06±3.57 mm; Fig. 5B) and in neurons expressing
exogenous P2Y13 (328.02±10.79 mm vs 131.44±4.81 mm;
Fig. 5E), in both cases above that of their respective control
neurons (180.25±3.89 mm or 193.67±6.00 mm). Treatment with
the cAMP antagonist, cAMPS-Rp (20 mM), attenuated the
increase in axon length produced by ADP or inhibiting P2Y13
with MRS-2211 (Fig. 5A,B).
The axon elongation provoked by suppressing P2X7 was
abolished by the adenylate cyclase antagonist SQ-22536 and by
the cAMP antagonist cAMPS-Rp. Furthermore, the inhibitory
effect of P2X7–GFP expression on axonal elongation was
reversed by the administration of forskolin or the PDE4
inhibitor (Fig. 5D,F). Taken together, these results demonstrate
that P2Y1 and P2Y13 receptors exert opposing regulatory effects
on adenylate cyclase activity, and that P2X7 negatively regulates
adenylate cyclase activity. These findings raise the question of
whether the coordinated activity of these three receptors and their
extracellular agonists can together modulate axon elongation
through a common pathway involving adenylate cyclase, cAMP
and PKA.
Adenylate cyclase 5 coordinates the regulation of axon
elongation mediated by P2Y1, P2Y13 and P2X7
All six mentioned adenylate cyclases (AC1, 3, 5, 6, 8 and 9)
can be activated by Gq or inhibited by Gi proteins, but only AC5
and AC6 are inhibited by sub-micromolar concentrations (0.2–
0.6 mM) of Ca2+ (Cooper, 2003; Guillou et al., 1999), such as
those produced by Ca2+ entry through the ATP membrane
receptor P2X7 (Leon et al., 2006). However, AC5 is also
activated by PKCf (Kawabe et al., 1994), which in turn has been
implicated in axon establishment (Schwamborn and Puschel,
2004) and binds to Gaq proteins (Garcia-Hoz et al., 2010). In fact,
PKCf inhibition did significantly impair axonal elongation
mediated by ADP or BBG (Fig. 6A,D). The axon elongation
produced by MRS-2211 (265.11±10.77 mm vs 141.71±3.59 mm
in control neurons) was also blocked by PKCf inhibition
(125.73±5.71 mm; Fig. 6A,D). However, PKCf inhibition did
not reduce axonal elongation when adenylate cyclases were
activated by forskolin (Fig. 6D). These data demonstrate that
PKCf mediates an adenylate-cyclase-dependent mechanism
triggered by ADP, which can be negatively regulated by
P2Y13 and P2X7 receptor activation.
Thus, we investigated the possibility that the AC5 adenylate
cyclase isoform co-ordinates the activities of P2Y1, P2Y13 and
P2X7 receptors during axon elongation.
In hippocampal neurons, AC5 was found in the soma, as well as
in a distal gradient in the axon and the actin region of the growth
cone, and to a lesser extend in minor neurites, similar to the
receptors P2Y1, P2Y13 and P2X7 (Fig. 6B; Fig. 1) (Diaz-
Hernandez et al., 2008). NKY80 (10 mM) is a highly selective
inhibitor of AC5 (Onda et al., 2001) that impaired ADP-mediated
axon elongation in hippocampal neurons at 1 to 3 DIV
(170.92±14.04 mm vs 253.38±11.48 mm in ADP-treated neurons
vs 201.34±7.62 mm in control neurons; Fig. 6C,E). Similarly, axon
elongation following P2Y13 inhibition with MRS-2211 was
abolished by NKY80, although it had no effect on axon
elongation in neurons treated with 2 mM dbcAMP (Fig. 6E).
Moreover, axon growth mediated by Gq activation (with rPMT) or
Gi inhibition (with pertussis toxin) was impaired by AC5
inhibition (Fig. 6E).
Next, neurons were nucleofected with plasmids expressing
P2Y1–GFP, or interference shRNAs for P2X7 or P2Y13 and
treated with NKY80 at 1 to 3 DIV (Fig. 6F,H). Although P2Y1–
GFP expression promoted axon elongation, this effect was
impaired by inhibiting AC5 with NKY80. Similarly, NKY80
attenuated the increases in axon elongation observed in neurons
expressing P2X7 or P2Y13 shRNAs.
Nucleofection of neurons with AC5 interference shRNAs
produced similar effects to the pharmacological inhibition of
AC5 (Fig. 6G,I). Axon elongation was reduced in neurons
expressing AC5 shRNA (141.54±4.68 mm vs 183.35±6.06 mm
in those expressing scrambled shRNA), and the increase in axon
elongation produced by ADP (275.36±9.55 mm), MRS-2211
(278.13±9.15 mm) and BBG (275.96±11.01 mm) treatment in
scrambled-shRNA-nucleofected neurons were abrogated in
neurons expressing AC5 shRNA (160.06±6.59, 168.31±7.24
and 153.65±6.91 mm, respectively). AC5 shRNA expression
failed to reduce axonal elongation in neurons treated with
forskolin or dbcAMP (Fig. 6I).
Finally, neurons were nucleofected with a plasmid expressing
a FRET-based biosensor to detect cAMP levels (ICUE3)
(DiPilato and Zhang, 2009). Neurons were treated with ADP
(5 mM) or the P2X7 antagonist BBG (100 nM), alone or in the
presence of NKY80 (10 mM), which was added 30 minutes
before treatment (Fig. 7). Both ADP and BBG increased by 20–
30% cAMP levels in the distal region of the axon (Fig. 7D,E)
compared with the normalized value before treatment (Fig. 7E).
These increases were abolished by pre-treatment with NKY80.
As a control, neurons were treated with forskolin in the presence
or absence of NKY80. In both cases cAMP levels were similar to
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Fig. 6. Adenylate cyclase 5 activity is required for proper axonal elongation in response to ADP or P2X7 inhibition. (A,D) Hippocampal neurons cultured
from day 1 to day 3 in vitro in the presence or absence of the PKCf inhibitor, PKCf pseudosubstrate (10 mM) in combination with ADP 5 mM, BBG 100 nM,
MRS-2211 5 mM or forskolin 5 mM. Neurons were stained with anti-MAP2 and anti-Tau-1 antibodies. Graph in D shows the mean axonal lengths ± s.e.m. from
three independent experiments. (B) Distribution of adenylate cyclase 5 in hippocampal neurons at 3 DIV. Arrow indicates the AC5 in the distal region of the axon.
Right panels show the distal region of the axon stained for AC5 and F-actin. Scale bar: 100 mm. (C) Hippocampal neurons treated from day 1 to day 3 in vitro with
ADP (5 mM) in the presence or absence of the adenylate cyclase 5 inhibitor NY80 (10 mM). Scale bar: 100 mm. (E) Mean axon lengths ± s.e.m. of 3 DIV neurons
treated with vehicle (black bars) or NKY80 (white bars), in combination with ADP (5 mM), the P2Y13 antagonist MRS-2211, dbcAMP (2 mM), rPMT or PTX.
Note that addition of dbcAMP impaired the inhibitory effect of NKY80 on axon growth; ***P,0.001. Data are from three independent experiments analyzing
100 neurons for each condition in each experiment. (F,H) Neurons nucleofected with GFP, P2Y1–GFP, scrambled shRNA, P2X7 shRNA or P2Y13 shRNA were
cultured from day 1 to day 3 in vitro with vehicle or the adenylate cyclase 5 inhibitor, NKY80. (F) Representative images of these neurons. (H) Mean axonal
lengths ± s.e.m. from three independent experiments analyzing 100 neurons for each condition in each experiment; ***P,0.001. (G,I) Neurons were nucleofected
with scrambled shRNA or AC5 shRNA. (G) Representative images of 3 DIV neurons. (I) Mean axon length ± s.e.m. of neurons shown in G cultured in the
presence of the indicated compounds at the concentrations shown previously. Scale bars: 100 mm.
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those observed following exposure to ADP or BBG. Moreover,
inhibition of PKA, a cAMP-dependent kinase, abolished the
increase in axon elongation produced by ADP or MRS-2211
(Fig. 7F). Taken together, these results demonstrate that
adenylate cyclase 5 is a common mediator of the axon
elongation regulated by P2Y1, P2Y13 and P2X7 receptors in
response to extracellular ADP and ATP.
ADP regulates the PI3K pathway
Initial axon establishment was not impaired by P2Y1 shRNA,
P2X7–GFP, P2Y13 expression or AC5 shRNA nucleofection,
suggesting that these purinergic receptors act through a common
signaling pathway to specifically regulate axon elongation.
Enhanced axon growth following P2X7 inhibition appears to be
mediated through the phosphoinositide 3-kinase (PI3K)–Akt–
GSK3 pathway (Diaz-Hernandez et al., 2008) and, moreover,
P2Y13 activity can regulate GSK3 phosphorylation (Ortega et al.,
2008). Thus, we examined whether the effects of ADP in axon
elongation were mediated by the PI3K pathway. In 3 DIV
hippocampal neurons, Akt and GSK3 phosphorylation was
augmented following acute administration of ADP (5 mM:
Fig. 8F,G). When PI3K was inhibited by the presence of LY-
294002 (10 mM) at 1 to 3 DIV, the axon elongation induced by
ADP or MRS-2211 was suppressed in both cases (Fig. 8A,C).
Hippocampal neurons expressing the P2Y13 receptor or treated
with the P2Y1 antagonist, MRS-2179, were cultured from
day 1 to day 3 in vitro in the presence of a GSK3 inhibitor
(AR-A014418; 20 mM). The inhibition of GSK3 reversed
the inhibitory effects of both P2Y1 inhibition and P2Y13
expression on axon elongation (Fig. 8B,D,E). Moreover, P2Y1
inhibition diminished the phosphorylation of Akt and GSK3
(Fig. 8F,G). All together, these results suggest a regulation of
adenylate cyclase 5 by ADP, ATP, P2Y1, P2Y13 and P2X7
receptors, through G proteins and extracellular Ca2+ entry. This
modulates cAMP levels and PKA function, regulating the input
Fig. 7. AC5 inhibition impairs the increase in cAMP levels at the distal region of the axon generated by ADP or BBG. (A–C) Hippocampal neurons
nucleofected with the FRET biosensor ICUE3. After 2 DIV, neurons were treated with ADP or BBG and processed as described in the Materials and Methods.
Pseudocolor images show FRET signals obtained from 2 DIV neurons before or after addition of ADP for 5 minutes. Pseudocolor images were obtained using Adobe
Photoshop CS4 software. The white rectangles indicate the area measured and the grey rectangles indicate the area of background measured. Grayscale images in C
show the FRET signal obtained after 5 minutes treatment with ADP or BBG. (D) Mean (± s.e.m.) FRET signal (YFP/CFP) from four different neurons treated as
described in the Materials and Methods section with the compounds indicated in the figure. (E) Mean (± s.e.m.) FRET signal obtained every 15 seconds during the
treatment with ADP, BBG or forskolin in the presence or absence of NKY80 normalized to the base line. Dashed lines indicate the time of treatment with ADP,
forskolin or BBG, and the normalized base line. (F) Mean axonal length of 3 DIV neurons treated from day 1 to day 3 in vitro with ADP, MRS-2211, rPMT or PTX,
alone (black bars) or in combination with the PKA inhibitor, H-89 (white bars). Data are the means ± s.e.m. of three independent experiments.
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of purinergic receptors signaling on the PI3K–Akt–GSK3
pathway (Fig. 8H).
Discussion
Purines and purinergic receptors have been implicated in a
variety of physiological and pathological conditions, including
neurotransmission, brain development, inflammation, pain,
central nervous system injury, neuropsychiatric disorders and
neurodegenerative diseases (Burnstock, 2007; Burnstock, 2008).
Purinergic receptors have been identified at early stages of brain
developmental when they regulate stem cell proliferation
(Burnstock and Ulrich, 2011). However, their role in the
development of neuronal morphology and axon growth remains
largely unknown. We previously demonstrated that ATP, acting
at the purinergic P2X7 receptor, negatively modulates axon
growth, generating an increase in calcium at the distal axon
(Diaz-Hernandez et al., 2008), whereas inhibition or suppression
of this receptor promotes axon elongation. The present study
demonstrates that ADP enhances axon growth in cultured
hippocampal neurons through the activation of the
metabotropic P2Y1 receptor. Both ADP and P2Y1 have been
previously described as regulators of neurosphere proliferation
(Mishra et al., 2006). P2Y1 is also necessary for proper migration
of intermediate neuronal progenitors to the neocortical
subventricular zone (Liu et al., 2008). Our results show that
P2Y1 function is necessary for proper axonal elongation, which
can be downregulated by the action of ADP at the P2Y13
receptor or the activation of the P2X7 receptor. The overall
positive results in axon elongation promoted by ADP might be
the result of the higher expression of P2Y1 than P2Y13 receptors,
as shown in supplementary material Fig. S1. The contrasting
effects of P2Y1 and P2Y13 activation on axon elongation are
consistent with their opposing roles in the control of pain or
insulin secretion (Amisten et al., 2010; Malin and Molliver,
2010). Both P2Y1 and P2Y13 are expressed in the distal region
of the axon, similar to P2X7 (Diaz-Hernandez et al., 2008). Thus,
Fig. 8. The axon-elongating effects of ADP are mediated by the PI3K–Akt–GSK3 pathway. (A,B) Hippocampal neurons cultured from day 1 to day 3 in vitro
in the presence of vehicle, the PI3K inhibitor LY-294002 (A) or the GSK3 inhibitor AR-014418 (B) in combination with ADP, antagonists of P2Y13 (MRS-2211)
or P2Y1 (MRS-2179) or following nucleofection with the P2Y13 receptor. (C–E) Mean axonal lengths ± s.e.m. of neurons shown in A and B. Axons were
identified as Tau-1-positive processes. Data are from three independent experiments analyzing at least 100 neurons for each condition in each experiment;
***P,0.001. (F,G) Quantification of Akt and GSK3 phosphorylation in extracts of hippocampal neurons cultures treated with ADP (5 mM) or the P2Y1
antagonist MRS-2179, for 5 or 15 minutes. Data are the means ± s.e.m. of three independent experiments; *P,0.05. Representative western blots from each
experiment are shown below the graphs. Actin was used as a loading control. (H) Proposed model of the intracellular mechanisms that coordinate the action of
P2Y1, P2Y13 and P2X7 receptors in regulating axon elongation.
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in both normal and pathological conditions, variations in P2Y1,
P2Y13 or P2X7 membrane expression, or extracellular ATP and
ADP concentrations, can modulate axon elongation. In this sense,
the different ectonucleotidase families that modify the number of
phosphates in adenine nucleotides could be important regulators
(Langer et al., 2008). For example, expression in cultured
neurons of tissue non-specific alkaline phosphatase (TNAP),
which reduces extracellular ATP levels, improves axonal
growth (Diez-Zaera et al., 2011). Our results suggest that
axon elongation is regulated through the coordination of the
ionotropic ATP-gated P2X7 receptor and ADP-activated P2Y
receptors. Thus, in the absence of elevated concentrations of
extracellular ATP, P2Y1 receptors can potentiate axonal
elongation, and this action might be partially controlled by
P2Y13 receptors and P2X7 receptors. However, after different
kinds of ‘acute’ CNS injury (e.g. ischemia, hypoxia, mechanical
stress, axotomy), extracellular ATP can reach high
concentrations, up to the millimolar range, flowing out from
cells into the extracellular space, exocytotically, by
transmembrane transport, or as a result of cell damage (Franke
and Illes, 2006). In that case, P2X7 activation by high
concentrations of extracellular ATP can negatively modulate
axonal elongation. In the case of acute spinal cord injury, P2X7
inhibition substantially improves functional recovery and
diminished cell death in the peritraumatic zone (Wang et al.,
2004). Moreover, P2 purinergic receptors are also involved in
neurodegenerative diseases. In the case of Alzheimer disease,
P2X7 receptor expression is upregulated (Parvathenani et al.,
2003) and P2Y1 receptor expression shows an altered distribution
in human AD brain (Moore et al., 2000).
The modulation of axon elongation by three distinct purinergic
receptors and varying concentrations of their agonists suggests that
their regulatory effects are coordinated at a common intracellular
checkpoint. cAMP is a second messenger with regulatory effects
on axon formation and elongation (Shelly et al., 2010). Adenylate
cyclase is implicated in multiple pathways that modulate axonal
growth, both positively and negatively, in developmental and
pathological conditions. For example, elevation of intracellular
cAMP levels by dbcAMP or inhibition of PDE4, can overcome
myelin inhibition both in vitro and in vivo (Lu et al., 2004;
Nikulina et al., 2004; Pearse et al., 2004).
Our results show that P2Y1 activation and P2X7 inhibition
both increase cAMP levels at the distal region of the axon.
One adenylate cyclase isoform, AC5, is regulated both by G
proteins (Willoughby and Cooper, 2007) and submicromolar
concentrations of Ca2+ (Cooper, 2003; Guillou et al., 1999).
Inhibition of AC5 blocks the axon elongation promoted by
activation of P2Y1 receptor or Gq, or inhibition of Gi proteins,
and it impairs the axon elongation produced by ADP or P2X7
inhibition. Gq proteins activate phospholipase C (PLC) that in
turn can activate PKCs, including PKCf (van Dijk et al., 1997).
Moreover, PKCf associates to Gq upon G-protein-coupled
receptor activation (Garcia-Hoz et al., 2010). This activation
of PKCf can stimulate AC5 activity (Kawabe et al., 1994;
Willoughby and Cooper, 2007). Indeed, we demonstrate that
inhibition of PKCf impairs the axon elongation produced by
ADP, P2Y13 inhibition or P2X7 inhibition. The reduction in
axonal elongation produced by PKCf inhibition is avoided by
adenylate cyclase activation, placing PKCf upstream of
adenylate cyclase 5, and being activated by the P2Y1 receptor.
The activation of AC5 by PKCf is, in turn, regulated in the
opposite way by P2Y13, Gi and P2X7. In the case of P2X7
inhibition, retinoic-acid-induced differentiation of N2a cells has
been shown to decrease P2X7 receptor levels (Wu et al., 2009)
but also, to increase AC5 mRNA levels during P19 cell
differentiation (Lipskaia et al., 1997). AC5 mRNA is expressed
in the striatum and hippocampus of the adult brain (Kheirbek
et al., 2009), and it increases in the hippocampus during post-
natal development up to day 14 (Matsuoka et al., 1997). Studies
in AC5 knockout mice demonstrate that AC5 is involved in a
signaling pathway in corticostriatal plasticity and striatum-
dependent learning. Moreover, loss of AC5 compromises the
ability of both contextual and discrete cues to modulate
instrumental behavior (Kheirbek et al., 2010; Kheirbek et al.,
2009), and the AC5 knockout mice show striking anxiolytic and
antidepressant phenotypes in standard behavioral assays
(Krishnan et al., 2008). Finally, AC5-knockout mice have
markedly attenuated pain-like responses in neuropathic pain
models (Kim et al., 2007), in accordance with the proposed roles
of P2Y1 and P2Y13 in pain (Malin and Molliver, 2010). Our
results demonstrate that AC5 protein is found in the soma and
shows an increasing distal gradient along the axon and axonal
growth cone. This distribution of AC5 in the axon mirrored the
expression of the three purinergic receptors of interest in
hippocampal neurons, and the localization of adenylate cyclase
(Mizuhashi et al., 2001) and PKA (Sato et al., 2002).
Signaling through each of the three purinergic receptors can
enhance or diminish the velocity of axon growth, but in no case
was axon formation impaired. The co-ordination of these
signaling pathways by adenylate cyclase 5 could be a key
means to regulate a main pathway involved in axon growth and
neuronal connectivity. Taken together with our previous findings,
our results indicate that activation of P2Y1 potentiates the PI3K–
Akt–GSK3 pathway to promote axon elongation, whereas ATP
exerts an opposing effect, downregulating the signaling through
this pathway and inhibiting axon growth. ADP activation of
P2Y1 increases Akt and GSK3 phosphorylation while promoting
axon elongation, an effect previously demonstrated following
P2X7 inhibition (Diaz-Hernandez et al., 2008). This enhanced
elongation can be impaired by inhibiting PI3K, whereas the
attenuation of axon growth by P2Y1 inhibition can be
counteracted by inhibiting GSK3, and such inhibition has been
previously shown to induce axonal elongation (Garrido et al.,
2007). Further studies will be necessary to fully elucidate the
complex signaling network that unites adenylate cyclase 5,
cAMP and PKA, and the PI3K–Akt–GSK3 pathway. The
complex coordination of purines and purinergic receptors
described in our work do not exclude that other parallel
signaling pathways regulated by these receptors might also be
involved in the regulation of neuronal development and function.
However, on the basis of the present findings, we can propose a
model whereby two purine nucleotides, ATP and ADP, control
the activity of three purinergic receptors, P2Y1, P2Y13 and
P2X7, in response to changes in extracellular purine
concentrations in both normal and pathological conditions.
These interactions positively or negatively influence adenylate
cyclase 5 activity, thereby modulating the capacity of PKA and
neurotrophic factors to activate the PI3K–Akt–GSK3 pathway.
Accordingly, the development of P2Y1-specific agonists,
combined with specific antagonists of P2X7 and P2Y13, might
provide an efficient means of treating the brain diseases
associated with the reduction of synaptic contacts, neuronal
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death or axonal degeneration, by promoting the arrival of axons
and new synapse generation.
Materials and Methods
Reagents
The following reagents were used in this study (catalog nos are given in
parentheses): ATP from Roche, ADP (A2754), 2meSADP (M152), forskolin
(F6886), H89 (B1427) and NKY80 (N2165), all from Sigma-Aldrich; MRS-2211
(2402), cAMPS-Rp (1337) and MRS-2179 (0900) from Tocris; pertussis toxin
(G100-0050) from Biomol; Pasteurella multocida toxin, rPMT (512743), U-73122
(662035), SQ-22536 (568500), phosphodiesterase 4 inhibitor (3,5-dimethyl-1-(3-
nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester, 524717), LY-2940002
(440202), AR-A014418 (361549) and PKC pseudosubstrate inhibitor,
myristoylated (539624), all from Calbiochem. Commercial antibodies against the
following proteins were used: P2Y1 and P2Y13 (Alomone, Jerusalem, Israel); P2X7
(Abcam); Akt (Santa Cruz Biotechnology); a-tubulin and b-actin (Sigma);
phosphorylated GSK (at amino acid S9/S21), phosphorylated Akt (at amino acid
S473) and GADPH (Cell Signaling); GSK3 (Invitrogen-Biosource); anti-adenylate
cyclase 5 (Abcam); and Tau-1 and MAP2 (Millipore). Oligonucleotides for
quantitative RT-PCR were obtained from Applied Biosystems.
Cell culture
Hippocampal neuronal cultures were prepared as described previously (Banker and
Goslin, 1988). Briefly, the hippocampus was removed from E17 mouse embryos
and after dissection and washing three times in Ca2+- and Mg2+-free Hank’s
balanced salt solution (HBSS), the tissue was digested in the same solution
containing 0.25% trypsin for 15 minutes at 37 C˚. The hippocampi were then
washed again three times in Ca2+- and Mg2+-free HBSS and dissociated with a fire-
polished Pasteur pipette. The cells were counted, resuspended in plating medium
(MEM, 10% horse serum, 0.6% glucose) and plated at a density of 5000/cm2 on
polylysine-coated coverslips (1 mg/ml). Neurons were incubated at 37 C˚ for
2 hours before switching them to neuronal culture medium (Neurobasal, B-27,
glutamax-I). To analyze the effect of P2Y receptor agonists and antagonists, the
compounds were added to the cultured neurons 1 day after plating at the
concentrations indicated, maintaining them for a further 48 hours. For biochemical
experiments hippocampal neurons were plated at a density of 200,000/cm2 on
60 mm plates coated with polylysine (0.5 mg/ml). Before plating, the different
plasmids were nucleofected into the neurons using the Amaxa nucleofection kit
according to the manufacturer’s instructions for hippocampal neurons. Only
scattered glial cells appeared after 3 DIV, and our neuronal cultures were 99%
pure.
HEK-293T cells were maintained in DMEM (Gibco) supplemented with 10%
(v/v) fetal calf serum (FCS). The cells were resuspended 1 day before transfection,
and plated at a density of 105 cells/cm2, and they were maintained in medium
containing 0.5% FCS. HEK-293T cells were transfected with Lipofectamine 2000
(Invitrogen) according to manufacturer’s instructions.
Plasmids
Full-length human P2Y1 cDNA (cDNA clone number MGC: BC074784;
Geneservice Ltd) was subcloned into the EcoRI and BamHI sites of the
mammalian pEGFP-N1 expression vector after PCR amplification with the
primers: 59-CTAGGAATTCATGACCGAGGTGCTGTGGCC-39 and 39-
CTAGGGATCCGGCAGGCTTGTATCTCCATTCT-59. The full-length human
P2Y13 cDNA was purchased from Open Biosystems (cDNA clone number:
BC041116). P2Y1 and P2Y13 receptor knockdown was achieved using RNA
interference (RNAi), applying a vector-based shRNA approach. The shRNA target
sequences 59-GCTGTGTCTTACATCCCTTTC-39 or 59-GCATCTCCGTGTAC-
ATGTTCA-39 were selected for P2Y1, and 59-CCTTTCCGACTCACACCTT-39
or 59-CAGCTGTTTATTGCTAAA-39 for the P2Y13 receptor, in accordance with
a previously reported rational design protocol (Reynolds et al., 2004). The P2X7
expression plasmids and shRNA used here have been described previously (Diaz-
Hernandez et al., 2008). As a control we used the firefly luciferase-targeted
oligonucleotide, 59-CTGACGCGGAATACTTCGA-39. Synthetic forward and
reverse 64-nucleotide oligonucleotides (Sigma Genosys) were designed,
annealed and inserted into the BglII–HindIII sites of the pSUPER.neo.GFP
vector (OligoEngine, Seattle, WA) following the manufacturer’s instructions.
Nucleofected neurons were identified by the expression of green fluorescent
protein (GFP) from this vector. The adenylate cyclase 5 interference shRNAs (79
and 84) and control scrambled shRNA were purchased from Origene (TG506651).
FRET imaging and analysis
Hippocampal neurons were nucleofected with a plasmid expressing the FRET
biosensor ICUE3 (DiPilato and Zhang, 2009). Neurons were cultured for 2 DIV
and examined with a C9100-02 CCD camera (Hamamatsu) and an Axiovert200
Zeiss microscope, using a 75W/2 Xenon XBO lamp and a 406/1.3 NA objective
(Zeiss). The excitation wavelength used was 422–432 nm, and emission
wavelengths were separated with a double dichroic filter (440–500 nm and 510–
610 nm), with 460–500 nm and 528.5–555.5 nm emission filters for CFP and YFP
fluorescence, respectively. Images were collected and analyzed with Metamorph
7.1 r2 software (Universal Imaging) and live images were acquired for 120–
140 mseconds at 15-second intervals. For global manipulation of cAMP signaling,
pharmacological agents were applied to the bath after 150 seconds of baseline
recording. The intensity of the CFP and YFP fluorescence was measured at the
distal region of the axon of hippocampal neurons using ImageJ software. For the
ratiometric FRET analysis, the background was subtracted from the CFP and YFP
signals of the defined distal region of the axon (background intensity was
calculated from a cell-free region using ImageJ software), which were then
normalized to the control value (averaged over 150 seconds of baseline recording),
and the FRET value was calculated as the ratio of the YFP:CFP signal. Neuronal
medium was switched to Neurobasal medium without Phenol Red 30 minutes prior
to analysis. The concentrations of pharmacological agents applied to the bath were
as follows: ADP, 5 mM; BBG, 100 nM; and forskolin, 5 mM. These treatments
were applied either alone or following a 30-minute preincubation with NKY80
(10 mM) prior to image acquisition, and the compounds tested remained present
throughout the experiment.
Immunocytochemistry
Neurons were cultured for 3 DIV followed by fixation in 4% paraformaldehyde for
20 minutes. Non-specific binding was blocked with 0.22% gelatin and 0.1% Triton
X-100 in 0.1 M phosphate buffer. Cells were then incubated with primary
antibodies for 1 hour at room temperature, washed and incubated with Alexa-
Fluor-conjugated secondary antibodies (1:1000) and Alexa-Fluor-594-conjugated
phalloidin (1:100). The coverslips were mounted using Fluoromount G (Southern
Biotech) and images acquired on a LSM510 confocal microscope coupled to an
Axiovert 200M (Zeiss) microscope. Axon length and ramifications was analyzed
with the NeuronJ program and the fluorescence intensity was evaluated using the
RGB color profiler tool of the ImageJ software. Images were processed and
presented using Adobe Photoshop and Illustrator CS3.
Western blotting
Cultured neurons were lysed and homogenized in a buffer containing: 20 mM Hepes
pH 7.4, 100 mM NaCl, 10 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate,
10 mM EDTA and protease inhibitors (2 mM phenylmethylsulphonyl fluoride,
10 mg/ml aprotinin, 10 mg/ml leupeptin and 10 mg/ml pepstatin). Proteins were
separated on 10% SDS-PAGE gels and transferred to nitrocellulose membranes. The
experiments were performed using primary polyclonal antisera (and dilutions) against:
P2Y1 (1:50); P2Y13 (1:50), Akt (1:1000); pS473Akt (1:1000); pS9/21GSK-3
(1:1000) or monoclonal antibodies against a-tubulin (1:1000); GSK-3 a/b (1:1000)
and b-actin (1:1000). The membranes were probed overnight at 4 C˚ with the selected
antibodies in 5% BSA and then with a secondary goat anti-mouse monoclonal
antibody or goat anti-rabbit polyclonal antiserum (both at 1:5000; Amersham) to
detect the primary antibodies. Antibody binding was visualized by ECL (Amersham).
Statistics
All experiments were repeated at least three times and the results are presented as
the means ± s.e.m. or as a box-plot showing the distribution of axonal length of all
neurons from at least three experiments. Axon length was quantified in at least 100
neurons for each condition and experiment, and all axons were identified as Tau-1-
positive processes. Statistical differences were determined by ANOVA using the
SigmaPlot software.
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